PYCR1 and neoplasm: In summary, in parallel with the original hypothesis supporting the use of anti-angiogenic drugs in tumors, our data suggest that inhibition of PYCR1 may push hypoxic tumor regions into a non-viable state, making the overall tumor more amenable to conventional therapies whose efficacy suffers in hypoxia.